Catalog
Research Compounds
Every product below links to a vetted affiliate vendor. Purity certificates are available from each supplier. For research use only.
Body Composition
Semaglutide (GLP-1)
GLP-1 receptor agonist widely studied for appetite regulation, blood sugar control, and body composition.
- Appetite regulation in clinical trials
- Glycemic-control research
- Body-weight reduction in STEP trials
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for synergistic effects on insulin secretion, fat metabolism, and appetite suppression — showing a greater magnitude of weight loss than semaglutide in head-to-head trials.
- Dual GIP/GLP-1 receptor agonism
- SURMOUNT trials: 20–22% body-weight reduction over 72 weeks
- ~20% greater weight loss than semaglutide in SURMOUNT-5
Retatrutide
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials recorded up to 24.2% body weight reduction — the highest of any compound in its class.
- Triple-receptor agonism (GLP-1/GIP/glucagon)
- Appetite research in Phase 2 trials
- Body-weight reduction in TRIUMPH-1 data
Cagrilintide
Long-acting amylin analog studied for appetite suppression and satiety signaling. Most researched in combination with semaglutide (as CagriSema), where Phase 3 data showed greater weight reduction than either compound alone.
- Amylin/calcitonin receptor agonism
- Satiety-signaling research distinct from GLP-1 pathway
- Studied alongside semaglutide in Phase 3 combination trials
Tesamorelin
Synthetic GHRH analog that stimulates endogenous growth hormone release. Studied for visceral fat reduction, body composition, and metabolic health.
- Visceral-fat reduction in RCTs
- GH-stimulation research
- Body-composition studies
AOD-9604
Synthetic fragment of human growth hormone (hGH 176-191) studied for its role in fat metabolism and lipolysis without affecting blood sugar or IGF-1 levels.
- Lipolysis research (hGH 176-191)
- Fat-metabolism study models
- No IGF-1 effect in studies